title: Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators.
abstract: We designed a cohort in order to assess the long-term effects of triple-drug antiretroviral combinations in 608 patients infected with human immunodeficiency virus type 1 (HIV-1). We recruited patients who had been previously treated with nucleoside analogues as well as treatment-naive patients who were starting triple-drug antiretroviral combinations consisting of nucleoside analogues, either alone or in combination with a protease inhibitor. After a median follow-up time of 22 months, the incidence rates of acquired immune deficiency syndrome-defining events and death were, respectively, 6.9 (95% confidence interval [CI], 5.3-8.8) and 2.9 (95% CI, 1.9-4.2) per 100 person-years. Advanced clinical stage of disease (P=.004), a low CD4(+) cell count (P=.002), and a low quality-of-life score (P=.001) at baseline were independent predictors of clinical progression. The initial triple-drug combination was modified a total of 647 times in 321 patients. The only independent predictor of treatment modification was previous exposure to a nucleoside analogue in patients who did not receive a new nucleoside analogue at inclusion (P=.001). Plasma HIV RNA values below 500 copies/mL were obtained in 88% of the treatment-naive patients and in 57% of the previously treated patients (P<.001). Compared with previously treated patients who received > or = 1 new nucleoside analogue at enrollment, previously treated patients who did not receive a new nucleoside analogue at enrollment were twice as likely to have plasma HIV RNA values >500 copies/mL at the last visit (adjusted odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.8), and the antiretroviral-naive patients were significantly less likely to have plasma HIV RNA values >500 copies/mL at the last visit (adjusted OR, 0.2; 95% CI, 0.1-0.4).
authors.affiliation: Service des Maladies Infectieuses, Hopital Rothschild, Paris, France.
authors.forename: P M
authors.initials: PM
authors.lastname: Girard
authors.forename: M
authors.initials: M
authors.lastname: Guiguet
authors.forename: D
authors.initials: D
authors.lastname: Bollens
authors.forename: I
authors.initials: I
authors.lastname: Goderel
authors.forename: M C
authors.initials: MC
authors.lastname: Meyohas
authors.forename: I
authors.initials: I
authors.lastname: Lecomte
authors.forename: G
authors.initials: G
authors.lastname: Raguin
authors.forename: J
authors.initials: J
authors.lastname: Frottier
authors.forename: W
authors.initials: W
authors.lastname: Rozenbaum
authors.forename: P
authors.initials: P
authors.lastname: Jaillon
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy / Q000821:virology
chemical_list: D012367:RNA, Viral